Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 40 of 116

  1. CLEE011X2107

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  2. CLEE011X2X01B

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  3. CLIN-01194-450

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  4. CLN-081

    Cullinan Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. CLN-081, CLN-081

    Cullinan Therapeutics

    Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

    phase 2 small molecule active

    1 trial

  6. CLXH254C12201

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

  7. CM-24 and Nivolumab - Dose Escalation

    PURPLE BIOTECH LTD.

    Solid Tumor

    phase 2 small molecule completed

    1 trial

  8. CMB305

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 mab terminated

    2 trials

  9. CMBG453B12206B

    Novartis Pharmaceuticals

    intermediate, high or very high risk MDS in adult patients chronic Myelomonocytic Leukemia - 2 (CMML-2) Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy

    phase 2 small molecule active

    1 trial

  10. CML1624

    Fondazione Telethon ETS

    BCR-ABL1+ Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  11. CMP-001

    Regeneron UK Limited

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule terminated

    1 trial

  12. CMP-001-009

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  13. CMUH-HO-NPC001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Head and Neck Carcinoma

    phase 2 small molecule completed

    1 trial

  14. CNAO 44 2021C

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  15. CNCT19

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-cell Lymphoma

    phase 2 mab completed

    1 trial

  16. CO40115

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  17. CO40778

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  18. CO41942

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  19. CO43810

    Hoffmann-La Roche

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  20. CO45813

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  21. CO46274

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  22. CORT125134-557

    CORCEPT THERAPEUTICS INC

    Gynecological Cancers

    phase 2 small molecule active

    1 trial

  23. CPGJ602

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  24. CPKC412A2218

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  25. CPT002/2018/PO001

    Fondazione Telethon ETS

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  26. CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection

    Jazz Pharmaceuticals Ireland Limited

    Colorectal Neoplasms

    phase 2 small molecule completed

    1 trial

  27. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    2 trials

  28. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia (AML) in Remission

    phase 2 small molecule active

    1 trial

  29. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Leukemia, Myeloid, Acute

    phase 2 small molecule completed

    1 trial

  30. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    7 trials

  31. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Lymphoid Leukemia

    phase 2 small molecule completed

    1 trial

  32. CPX-351

    Jazz Pharmaceuticals Ireland Limited

    Myeloid Neoplasm

    phase 2 small molecule active

    1 trial

  33. CR-001

    CRESCENT BIOPHARMA, INC.

    Locally Advanced / Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  34. CR6086-1-04

    Alphapharm Pty Ltd

    Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers

    phase 2 small molecule active

    1 trial

  35. CRB-601 monoclonal antibody

    Corbus Pharmaceuticals Holdings

    Solid Tumor

    phase 2 small molecule active

    1 trial

  36. CRB-701

    Corbus Pharmaceuticals Holdings

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  37. CRISP ITCC-053

    Disc Medicine

    Neuroblastoma (NBL), Rhabdomyosarcoma (RMS), Inflammatory Myofibroblastic Tumors (IMT), Other ALK/ROS1/MET-positive malignancies, Anaplastic Large Cell Lymphoma (ALCL)

    phase 2 small molecule active

    1 trial

  38. CRN09682

    Crinetics Pharmaceuticals Europe GmbH

    SST2-positive Neuroendocrine Neoplasms

    phase 2 small molecule active

    1 trial

  39. CRN09682-191

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced SST2-positive neuroendocrine neoplasms in adults

    phase 2 other active

    1 trial

  40. CS1001

    Cstone Pharmaceuticals Ireland Limited

    Advanced Refractory Solid Tumors

    phase 2 small molecule completed

    1 trial

  41. CSET 2020/3187

    The George Institute

    Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

    phase 2 other active

    1 trial

  42. CSET 2022-3571

    The George Institute

    Patients with hormone-receptor negative and HER2-negative (IHC 0, 1+ or IHC 2+/ISH-) breast cancer with early relapse while on (neo) adjuvant systemic treatment or within 12 months from the end of all treatments with curative intent.

    phase 2 other active

    1 trial

  43. CSET 2025/4053

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  44. CSET N° 2017/2523

    The George Institute

    Pancreatic well differentiated neuroendocrine tumors (NET)

    phase 2 other active

    1 trial

  45. CSET N° 2020/3188

    The George Institute

    Patients with hormone-receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-negative) advanced breast cancer (ABC) who have already received standard therapy for HR+/HER2-negative ABC, including only one line of chemotherapy for advanced/metastatic disease.

    phase 2 other active

    1 trial

  46. CSET N°2016/2454

    The George Institute

    Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

    phase 2 small molecule active

    1 trial

  47. CSET N°2017/2536

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  48. CSET N°2020/3138

    The George Institute

    Advanced hepatocellular carcinoma

    phase 2 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.